[Recombinant activated factor VII use for the bleeding implications prevention during central venous catheterization in pediatric patients with acute leucosis and thrombocytopenia].

Abstract

UNLABELLED:

Research objective was to develop an algorithm of the recombinant activated Factor VII (rFVIIa) prophylactic use for the bleeding implications prevention during central venous catheterization in Pediatric patients with acute leucosis and thrombocytopenia.

METHODS:

30 Pediatric patients with acute leucosis and thrombocytopenia received rFVIIa 30-120 microg kg(-1) before the internal jugular vein catheterization with ultrasound control. Comparative group 1 included 39 Pediatric patients without preventive haemostatic treatment; comparative group 2 included 30 patients received platelet concentrate.

RESULTS:

the first attempt catheterization numbers increased, the time of the catheterization was reduced, platelet aggregation was improved and the bleeding implications frequency was 6.6% in patients received rFVIIa before the internal jugular vein catheterization. 23.1%--in the comparative group 1; 26.7% in the comparative group 2.

CONCLUSION:

Ultrasound navigation and rFVIIa preventive use together improve internal jugular vein catheterization results.

• Authors: A M Sergeeva, V A Mazurok, I I Zakirov, V A Kichigin
• Journal: Anesteziologiia i reanimatologiia (Anesteziol Reanimatol) 2013 Jan-Feb Issue 1 Pg. 18-21 ISSN: 0201-7563 [Print] Russia (Federation)
• PMID: 23808247 (Publication Type: Comparative Study, Journal Article)

Chemical References

• Hemostatics
• Recombinant Proteins
• recombinant FVIIa
• Factor VIIa

Topics

• Adolescent
• Algorithms
• Catheterization, Central Venous (adverse effects, methods)
• Child
• Child, Preschool
• Dose-Response Relationship, Drug
• Factor VIIa (therapeutic use)
• Hemorrhage (etiology, prevention & control)
• Hemostatics (therapeutic use)
• Humans
• Infant
• Jugular Veins
• Leukemia (complications)
• Platelet Aggregation (drug effects)
• Platelet Transfusion
• Recombinant Proteins (therapeutic use)
• Thrombocytopenia (complications)
• Time Factors
• Ultrasonography, Interventional (methods)